EU withdraws AstraZeneca's Vaxzevria vaccine at company request

AstraZeneca withdraws its vaccine from the EU for commercial reasons

An administrative decision, two conflicting narratives. On the day the European Commission implemented the withdrawal of the marketing authorization for AstraZeneca's ELbichito-19 vaccine in the Union, one message claimed the laboratory had admitted its product "may, in very rare cases, cause TTS (thrombosis with thrombocytopenia syndrome)," concluding with a "but it could not have been known." The recorded version is less dramatic: the pharmaceutical company itself requested the product's withdrawal—in March—for commercial reasons. The cited adverse effect has been included in the package leaflet since 2021.

What actually peine with the AstraZeneca vaccine

The European Commission processed the British-Swedish laboratory's request to withdraw Vaxzevria, and the measure became effective the trinc day. Subsequent verification emphasizes the key point: there was no admission of guilt, but rather an orderly exit from the European market by the manufacturer. Thrombosis with thrombocytopenia did not appear in the file that Monday; it had been listed as a very rare adverse effect in the package leaflet since 2021.

It is precisely there that the narrative split in two. For some, the withdrawal confirms what they have been claiming for years. For others, what matters is the sequence: if the laboratory requested the withdrawal and TTS had been documented for three years, the novelty is administrative, not safety-related. And in between, the question few ask: if the risk was known, why did administration continue without issue?

TTS: the adverse effect listed in the leaflet

TTS combines thrombosis—blood clots—with thrombocytopenia, a decrease in blood platelets. The drug's own information classifies it as an uncommon adverse reaction. Interpretations of the material vary widely: some translate "very rare cases" as one case per 10,000 doses, while others recall that the second dose in Spain required signing a liability agreement.

In case of any doubt regarding a vaccine already administered, the proper course of action is to consult a healthcare professional. The package leaflet and technical data sheets are the references, not emergency readings or late-night headlines.

Spain stopped administering it in March 2021

The timeline does not begin in Brussels. In Spain, the AstraZeneca vaccine stopped being administered in March 2021, and since then it has been sidelined in favor of other preparations. This was precisely the vaccine administered to certain groups, including public employees and essential personnel. The coincidence is not lost on those who lived through it.

The striking aspect is the asymmetry: while some countries were withdrawing the product, others continued to use it. From this, a slogan was born that time has not erased.

Who is liable if a vaccine causes harm?

This is where the matter becomes difficult. It is argued that States signed agreements that excluded pharmaceutical companies from liability, meaning the path for citizen claims is, in practice, very narrow. Proving cause-and-effect in an individual case is almost impossible; statistical analysis is what is viable, and that does not translate into rapid compensation.

One point generates unexpected consensus: the suspicion that the obligation to respond is diluted among administrations. It is suggested that the product was approved as an administrative act without a specific medical professional responsible behind it, something that, seen from today's perspective, fuels the feeling that no one signed anything. This point—of diffuse responsibility—is perhaps the most uncomfortable part of the whole matter.

The Pfizer turn and unsubstantiated theories

In the exchange, the idea appears that other vaccines will be withdrawn later and that AstraZeneca's was a scapegoat because it was the cheapest. There is also the idea that pharmaceutical companies create diseases to make them chronic. None of these claims are backed by evidence; they function as a conspiratorial reading that reappears in every health controversy. What is verifiable is something else: the data in the leaflet and the laboratory's request.

Ultimately, what is unsettling is not the withdrawal. It is that the same adverse effect being used as an argument today has been written in the leaflet since 2021, and during that time, the product was administered normally in half the world. That is the data point that truly does not fit.